| 高艳艳,李巧莉,何玉萍.腹腔热灌注化疗治疗卵巢癌 60例[J].安徽医药,2021,25(5):1036-1039. |
| 腹腔热灌注化疗治疗卵巢癌 60例 |
| Treatment of ovarian cancer with hyperthermic intraperitoneal chemotherapy: 60 cases |
| |
| DOI：10.3969/j.issn.1009-6469.2021.05.048 |
| 中文关键词: 卵巢肿瘤 化学疗法，肿瘤，局部灌注 腹腔热灌注 肿瘤标志物 |
| 英文关键词: Ovarian neoplasms Chemotherapy, cancer, regional perfusion Hyperthermic intraperitoneal chemotherapy Tumor markers |
| 基金项目: |
|
| 摘要点击次数: 1404 |
| 全文下载次数: 374 |
| 中文摘要: |
| 目的观察腹腔热灌注化疗治疗晚期卵巢癌的临床效果。方法选取 2015年 4月至 2018年 4月在黄河三门峡医院接受治疗的卵巢癌病人 120例，对其进行卵巢癌肿瘤细胞减灭术，术后采用随机数字表法分为观察组和对照组，各 60例，对照组给予静脉化疗，观察组给予腹腔热灌注化疗联合静脉化疗，比较两组治疗后的肿瘤标志物 CA125、CA199、CA153、甲胎蛋白(AFP)、癌胚抗原( CEA)、人附睾蛋白 4(HE4)的情况，比较两组治疗后 1年、 2年复发率及生存率。结果观察组与对照组比较，观察组 CA125(1个月 52例比 40例， 3个月 58例比 44例)、 CA199(1个月 27例比 14例， 3个月 32例比 20例)、 CA153(1个月 40例比 32例， 3个月 50例比 38例)、 AFP(1个月 10例比 8例， 3个月 16例比 12例)、 CEA(1个月 12例比 10例， 3个月 18例比 14例)、 HE4(1个月 49例比 34例， 3个月 58例比 38例)在 1个月、 3个月时降至正常的例数高于对照组( P <0.05)观察组的 1年(63.33%比 75.00%)、 2年的复发率( 88.33%比 95.00%)低于对照组，观察组的 1年( 86.67%比 76.67%)、 2年生(63.33%比存率，50.00%)高于对照组。结论晚期卵巢癌病人在手术后进行热灌注化疗联合静脉化疗，对控制肿瘤的生长有明显作用，复发率更低，生存率更高，值得在临床工作中进一步开展与应用。 |
| 英文摘要: |
| Objective To investigate the clinical efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced ovarian cancer.Methods A total of 120 patients with ovarian cancer who were treated in Yellow River Sanmenxia Hospitalfrom April 2015 to April 2018 were enrolled and treated with ovarian cancer tumor suppressant surgery. After surgery, they were randomly divided into two groups. The control group received intravenous chemotherapy. The observation group received hyperthermic intraperitoneal chemotherapy combined with intravenous chemotherapy. The tumor markers CA125, CA199, CA153, AFP, CEA, HE4 after treatment, relapse rate and survival rate after 1 year and 2 years of treatment in the two groups of patients were compared.Results The number of cases in which CA125 (1 month 52 cases vs. 40 cases,3 month 58 cases vs. 44 cases),CA199 (1 month 27 cases vs. 14 cases,3 month 32 cases vs. 20 cases),CA153 (1 month 40 cases vs. 32 cases,3 month 50 cases vs. 38 cases),AFP (1 month10 cases vs.8 cases,3 month 16 cases vs. 12 cases),CEA (1 month 12 cases vs. 10 cases,3 month 18 cases vs. 14 cases), HE4 (1 month 49 cases vs. 34 cases,3 month 58 cases vs. 38 cases) were reduced to normal at 1 month and 3 months in the observation group was higher than in the control group. (P<0.05) .The recurrence rate for 1 year (63.33% vs. 75.00%) and 2 years (88.33% vs. 95.00%) in the observation group was lower than that of the control group, and the survival rate for 1 year (86.67% vs. 76.67%) and 2 years (63.33% vs. 50.00%) in the observation group was higher than that of the control group.Conclusion Hyperthermic intraperitoneal chemotherapy combined withintravenous chemotherapy in patients with advanced ovarian cancer after surgery has a significant effect on controlling the growth of thetumor, with lower recurrence rate and higher survival rate, which is worthy of further development and application in clinical work. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
